Skip to main content
Clinical Trials/CTRI/2020/02/023092
CTRI/2020/02/023092
Not yet recruiting
未知

Identifying association of gene polymorphism and Prakriti in responders and non responders to dual antiplatelet therapy in coronary artery disease patients

A0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: I22- Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Sponsor
A
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
A

Eligibility Criteria

Inclusion Criteria

  • 1\. North Indian ethnicity
  • 2\. CAD patients (stable angina, non ST elevation and ST elevation myocardial infarction) presenting to Cardiology OPD, AIIMS after 30days of PCI up to 180 days
  • 3\. Patients receiving dual antiplatelet therapy and on stable dose of clopidogrel upto 150 mg once a day and aspirin upto 150 mg once a day for a minimum period of 30 days
  • 4\. Willing to participate in the study

Exclusion Criteria

  • 1\. Patients under anti coagulation therapy
  • 2\. Use of intensified antiplateletagents other than standard dual antiplatelet therapy
  • 3\. h/o Bleeding disorders (Hemophilia, von Willebrand disease), hospitalization related to bleeding
  • 4\. Chronic kidney disease (eGFR \< 60 ml/min)
  • 5\. Any contraindications if elicited to antiplatelet therapy
  • 6\. Patients with hemoglobin \< 10
  • 7\. Patients with platelet count \< 100K
  • 8\. Patients with major surgery within 1 week
  • 9\. Patients with regular need of NSAID or prednisone(not taken in past 2 weeks)
  • 10\. Females with pregnancy or lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials